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Mitochondria are the energy-producing powerhouses of the cell.
Their function is dependent on proteins transcribed from nuclear and
mitochondrial DNA (mtDNA). Mitochondrial DNA is circular inthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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offspring irrespective of gender, as all mitochondria in the embryo orig-
inate from oocyte cytoplasm (Giles et al., 1980). With progressive ge-
netic technologies in detecting disease-associated mtDNA mutations,
over 300 rRNA/tRNA mutations (http://www.mitomap.org/foswiki/
bin/view/MITOMAP/MutationsRNA) and over 300 coding/control re-
gion point mutations have now been identiﬁed (http://www.
mitomap.org/foswiki/bin/view/MITOMAP/MutationsCodingControl).
Disruption of essential metabolic pathways in persons suffering
from mtDNA disease, especially in high energy-demanding organs,
leads to severe disability and early death. At present, no preventative
treatments are available to prospective parents who are afﬂicted and
wish to conceive (Pfeffer et al., 2012). Clinical diagnosis is challenging
due to varying symptoms and phenotypes, even within a single family.
This is due to mitochondrial heteroplasmy, where mutational load at
the cellular level determines phenotype: lowmutational loadwill result
in asymptomatic phenotypes or low severity, but once the number of af-
fected mitochondria exceed a certain threshold, patients become in-
creasingly symptomatic. There may also be unequal distribution of
mutated mtDNA between organs depending onmitochondrial segrega-
tion patterns during fetal development, giving rise to various pheno-
types depending on the levels of mutated mtDNA present and the
organs involved (Larsson and Clayton, 1995).
This review focuses on “mtDNA disease”, not “mitochondrial dis-
ease”, the latter referring to disorders that are caused by mutations in
both mtDNA and nuclear DNA. In the case of nuclear DNA mutations,
Mendelian genetics are applicable (Angelini et al., 2009), whereas
mtDNA mutations are inherited maternally (Giles et al., 1980). Only
around 20% of disorders involving defective mitochondrial oxidative
phosphorylation (OXPHOS) are accounted for by mutations in mtDNA
(Darin et al., 2001).
Research in both animals and humans has offered hope for the pre-
vention of mtDNA disease via assisted reproductive technology (ART)
techniques involving micromanipulation. This review explores tech-
niques that could be used for the prevention of mtDNA disease trans-
mission, their additional potential uses in the clinical setting and the
concern of mitochondrial-nuclear genome mismatch.
2. Mitochondrial transfer techniques
2.1. Pronuclear transfer
Pronuclear transfer (Fig. 1A) involves the transfer of pronuclei from
one zygote to another (Craven et al., 2010). This technique ﬁrst requires
fertilisation of healthy donated egg/s (provided by the mitochondrial
donor) with the intending male parent sperm. Simultaneously, the
intending mother's affected oocytes are fertilised with the intending
father's sperm. Both sets of fertilised oocytes are allowed to develop to
the early zygote stage where the pronuclei are visible. Using microma-
nipulation equipment, the pronuclei of zygotes formed from donated
oocytes are removed within a karyoplast, and discarded. Therapeutic
pronuclear transfer involves the movement of two pronuclei from the
affected zygotes (also in the form of a karyoplast), into the enucleated
healthy zygotes. The resulting zygotes contain nuclear DNA from each
of the intending parents and a donor's mtDNA.
Using thismethod, Craven et al. (2010) have demonstrated less than
2.0% carryover of mtDNA between abnormally fertilised zygotes that
possessed either one or three pronuclei. They also demonstrated that
pronuclear transferwas compatiblewith onward in vitro embryo devel-
opment. Blastocyst development rate was approximately half (17%) of
that found amongst normally fertilised embryos (32%). This can be ex-
plained by the lack of a reliable morphological factor that can be used
to differentiate between male and female pronuclei in zygotes. When
pronuclei were transferred from the abnormally fertilised zygotes in
this study, the authors could not be certain whether they were
reconstructing zygotes with one female and one male pronucleus. Ifthe resultant zygote is deﬁcient in one or the other genome, develop-
ment will be impaired.
A disadvantage from an ethical point of view is that half of the em-
bryos (affected zygotes whichwill be enucleated and have their nuclear
geneticmaterial transferred)will be destroyed. However, unlike spindle
transfer, in vitro fertilisation (IVF) can be performed if the sperm pa-
rameters so permit, and intracytoplasmic sperm injection (ICSI) is not
necessarily required. Another advantage of pronuclear over spindle
transfer is that pronuclei can be more easily visualised than spindles,
using a conventional invertedmicroscope. During the process of nuclear
transfer, the karyoplast is placed within the perivitelline space and then
allowed to fuse to the donor cytoplast using the inactivated viral vector
SeV (Sendai virus, also known as HVJ-E) (Tachibana et al., 2009; Craven
et al., 2010). This raises concern about the possible effects of a viral vec-
tor on an embryo or its development. Tachibana et al. (2009) demon-
strated the lack of SeV genetic material in reconstructed embryos by
reverse transcription (RT)-PCR analysis, indicating that the viral vector
does not pose any potential threats in the offspring or further genera-
tions. As this is a novel technique, pronuclear transfer has only been ap-
plied to abnormally fertilised zygotes, which possessed either one or
three pronuclei (Craven et al., 2010). This method needs to be assessed
in a primate animal model, as has been done with spindle transfer, in
order to prove its efﬁcacy and safety (Tachibana et al., 2009).
2.2. Spindle transfer
Spindle transfer (ST) (Fig. 1B) aims to achieve the same results as
pronuclear transfer – inheritance of parental nuclear DNA and donor
mtDNA in the offspring. In this method, the transfer of parental nuclear
DNA occurs before fertilisation (Tachibana et al., 2009). This technique
involves excision of the metaphase II spindle from the donor oocyte,
which will provide the cytoplasmic constituent (including mitochon-
dria) to the embryo. Again, containedwithin a karyoplast, the donor nu-
clear DNA will be discarded. The chromosome-spindle complex will
then be removed from the oocyte of the intending mother, and trans-
ferred to the enucleated healthy donor oocyte (Tachibana et al., 2009).
A rhesus macaque study using this technique resulted in the birth of
three healthy offspring (Tachibana et al., 2009). The presence of nuclear
DNA originating from spindle donors and mtDNA from recipient oocytes
was established though genetic analysis. No spindle donor mtDNA was
observed in the offspring, demonstrating efﬁcientmitochondrial replace-
ment. Postnatal follow up analysis into adulthood (from birth to 3 years
old) has shown that routine blood and body weight measurements
were comparable to age-matched controls (Tachibana et al., 2013).
The same research group has also implemented this technique in
human oocytes to study the feasibility of fertilisation, embryo develop-
ment and embryonic stem cell (ESC) yield (Tachibana et al., 2013).
Fertilisation rate in ST oocytes was comparable to controls (73% versus
75%, respectively). Although a substantial number of ST zygotes (52%)
contained abnormal numbers of pronuclei, showing abnormal
fertilisation, blastocyst development (62%) in normally fertilised zy-
gotes was similar to controls. ESC isolation rates from ST blastocysts
(38%) were also similar to controls, and all cell lines exhibited the pres-
ence of donor mtDNA only and normal karyotypes. The relatively high
incidence of abnormal fertilisation was surprising, as it was not ob-
served previously in the 2009 primate study. Possibly, human meiotic
spindles were prematurely activated during the ST procedure resulting
in impaired continuation of meiosis post fertilisation. Analysis after
immunolabeling with α- and β-tubulins revealed that some ST oocyte
spindles had prematurely progressed to late anaphase II (Tachibana et
al., 2013). ESCs derived from the abnormally fertilised zygotes exhibited
triploidy, stemming from the presence of two sets of the maternal ge-
nome. This ﬁnding showed that some oocytes failed to complete meio-
sis and the chromosomes failed to segregate into the second polar body,
probably resulting from premature activation. This study highlights the
efﬁcacy and potential use of ST for the prevention of mtDNA disease in
Fig. 1.Methods for prevention ofmtDNA disease transmission: (A) pronuclear and (B) spindle transfer. ICSI – intracytoplasmic sperm injection;mtDNA –mitochondrial DNA; nDNA – nuclear
DNA; IVF – in vitro fertilisation.
Reproduced from Reznichenko et al., 2015, with permission from SAJBL.
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recipient mitochondria and does not inhibit embryo development or
the derivation of stable stem cell lines.
ST has also been performed inmaturemetaphase II (MII) human oo-
cytes which were subsequently parthenogenically activated instead of
fertilised (Paull et al., 2013). This work too showed blastocyst develop-
ment post ST, and mtDNA carryover of less than 1%. mtDNA carryover
decreased in blastocysts and stem cells spindle donor mtDNA becameundetectable, and this situation persisted after passaging for more
than one year, clonal expansion, differentiation into neurons,
cardiomyocytes orβ-cells, and after cellular reprogramming.Mitochon-
drial function in ESCs and their differentiated phenotypes as assessed by
rates of respiratory chain enzyme activity and oxygen consumptionwas
determined to be comparable to controls (Paull et al., 2013). This ﬁnd-
ing illustrates that metabolic function is not disrupted post introduction
of donor mitochondria that are foreign to the nuclear genome.
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nuded before the procedure due to the need for zona pellucida thinning
and laser assisted zona drilling. Subsequently, the oocyte can only be
fertilised through ICSI. Another limitation is that this procedure is
more costly due to the fact that the spindle can only be visualised
using specialised equipment that is coupled to an imaging system that
uses polarised light birefringence. The chromosome-spindle complex
is a fragile structure that needs to be handled with utmost care, as the
DNA is not as stable as in pronuclei. Recently, another group has advised
that the ﬁrst polar body be removed along with the spindle from the
donor oocyte before the procedure, as the polar body can be resorbed
during later fusion of the karyoplast, and cause polyploidy (Greggains
et al., 2014). Another disadvantage is that chromosome scattering can
occur duringmetaphase II, and this evidence of spindle damage has pre-
viously been found to occur as a result of temperature ﬂuctuation
(Almeida and Bolton, 1995) and advanced maternal age (Battaglia et
al., 1996). Craven et al. (2011) recommend that spindle transfer should
be performed under highly regulated environmental conditions with
minimal risk of damage, that otherwise could result in aneuploidy dur-
ing manipulation of the spindle.
2.3. Ooplasmic transfer
Also referred to as cytoplasmic transfer, this form of mitochondrial
transfer entailsmovement of someooplasm, containingwild-typemito-
chondria, from a healthy donor oocyte into an affected one (Flood et al.,
1990) (Fig. 2). Theoretically, the consequent heteroplasmy in the
resulting embryo should lead to dilution of mutant mitochondria and
rescue of the defective mtDNA phenotype, at least to some extent. Suc-
cess however depends on the unpredictable nature of mitochondrial
segregation during fetal development and which organs will eventually
have levels of mutant mtDNA above the disease threshold. Ooplasmic
transfer has been reported in patients that had previously experienced
failed embryonic development, where the donated portion of ooplasm
is thought to provide mitochondria and other factors that support de-
velopmental competency (Van Blerkom et al., 1998; Huang et al.,Fig. 2. Ooplasmic transfer. Donor ooplasm is transferred to a recipient oocyte. Sperm is
injected simultaneously during the transfer to fertilise the denuded recipient oocyte.1999; Jacobs et al., 2006). Of concern is the ﬁnding in some studies of
an increased incidence of chromosomal abnormalities and birth defects
post ooplasmic transfer (Brown et al., 2006; Jacobs et al., 2006). This
raises doubt about the clinical use of this technique for women at risk
of transmitting mtDNA disease to their offspring.
Similarly to ST, ooplasmic transfer requires oocyte denudation be-
fore the procedure, which results in fertilisation only being possible
via ICSI. The sperm and donor ooplasm are introduced simultaneously
in one injection (Fig. 2).While ooplasmic transfer could provide a signif-
icant improvement in embryo development for patients who have
experienced repeated IVF failure, thismethodology does not necessarily
provide the best approach to the prevention of mtDNA disease
transmission and carries many risks related to abnormal embryo
development. Only small volumes of donor ooplasm can be transferred
(10–15% of the entire oocyte) and it is believed that this would provide
insufﬁcient amounts of donor mitochondria to “override” the mutant
mtDNA in the affected recipient oocyte (Thorburn et al., 2001; Taylor
and Turnbull, 2005; Brownet al., 2006; Jacobs et al., 2006). Furthermore,
it is uncertainwhether larger volumes could be transferred andwhat ef-
fect this will have on the ultrastructure of the recipient oocyte. For these
reasons, this technique has not been the primary focus of research for
the prevention of mtDNA disease.
2.4. Blastomere transfer
Blastomere transfer involves transplantation of a blastomere from
an affected embryo into an enucleated healthy donor oocyte (Fig. 3).
Similar to other methods, the embryo will inherit mtDNA from the
healthy donor oocyte cytoplasm, but it is unclear whether this tech-
nique can successfully preventmtDNAdisease in the resulting offspring.
An entire cell (a blastomere) is fused to the recipient oocyte, instead of
merely a karyoplast containingmostly nuclearmaterial (with very little
mitochondrial carryover). Indeed, bovine studies have revealed high
levels of mtDNA heteroplasmy in the resulting embryos (Steinborn et
al., 2000; Ferreira et al., 2007). This implies that the resulting offspring
will be heteroplasmic and therefore the same issues of mitochondrial
segregation and threshold effect will apply as discussed previously in
ooplasmic transfer. This questions the use of this technique for the pre-
vention of mitochondrial disorders. This methodology has not been ap-
plied clinically and no studies have been reported in humans, as it is
closely aligned to reproductive cloning and involves the samemicroma-
nipulation procedures, using postzygotic nuclear transplantation.
In cases of reproductive cloning in other mammalian species
(Bordignon et al., 2013; Hajian et al., 2013; Kamimura et al., 2013), al-
though the techniques have been perfected, manipulated embryos un-
dergo developmental failure and the resulting offspring are found to
succumb to early death, which is presumed to be coupled to unantici-
pated epigenetic events. Regarding somatic cell nuclear transfer
(SCNT), a genome-wide study revealed that although an oocyte has
the ability to epigenetically reprogram transplanted DNA, it cannot
fully replicate the DNA demethylation which occurs during natural
fertilisation. Consequently, atypical methylation patterns in promoter
and repetitive element regions cause disruption of characteristic devel-
opmental events and cell growth regulation (Peat and Reik, 2012). A
similar phenomenon could possibly occur following the transfer of blas-
tomere nuclei, although blastomeres are not differentiated (unlike so-
matic cells). Roberts (1999) hypothesised that the resulting embryo
may have impaired developmental potential.
3. Concern regarding mitochondrial-nuclear genome
incompatibility
The interaction between nuclear and mitochondrial gene products
ensures successful cell function through essential metabolic pathways.
Many nuclear-encoded proteins are transported tomitochondria to per-
form their respective functions within the electron transport chain.
Fig. 3. Blastomere transfer. A blastomere from an affected mother's embryo is transferred to a healthy donor oocyte.
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there is increasing concern over the possible incompatibility that this
could create in the communication network that exists between the nu-
cleus and mitochondria, which could have deleterious effects on the
metabolomics of a cell (Chinnery et al., 2014).
Although themitochondrial genome is highly conserved amongst all
human populations, it has been proposed that during human evolution
mtDNA missense mutations accumulated in non-African populations
during their migration to the northern hemisphere (Wallace, 2005).
This phenomenon served as an adaptation ofmitochondrial bioenerget-
ics tomore northern climates with the selectedmtDNA variants provid-
ing superior reproductive advantages under the pressure of the novel
environmental conditions (Ruiz-Pesini et al., 2004; Wallace, 2005).
Taken together with the presence of various mtDNA haplotypes
amongst different population groups today, it may therefore be advan-
tageous to select mitochondrial donors from the same ethnic group as
the affected recipient. This approach will increase the chance of similar
mitochondrial genome haplotypes and therefore compatibility with the
nuclear genome (Burgstaller et al., 2015).
Several murine studies have demonstrated the lack of any
mitonuclear incompatibility as normal healthy offspring are obtained
when breeding genetically distant mice (Battersby and Shoubridge,
2001; Gregorová et al., 2008; Cannon et al., 2011). ST in rhesus ma-
caques was performed purposefully using very divergent nuclear and
mtDNA haplotypes, and long-term follow up of these animals demon-
strated absence of anymetabolic malfunction or adverse health and de-
velopment (Tachibana et al., 2009, 2013). Research in this animal
model, the closest relative toman, has demonstrated thatmitochondrial
transfer should not compromise the functionality of mitonuclear inter-
actions. Normal development and differentiation was also observed in
human embryos and their derived ESCs after mitochondrial transfer
using “unmatched”mtDNA (Craven et al., 2010; Tachibana et al., 2013).
One must consider the many children born to interracial parents
with divergent haplotype groups. All of the offspring inherit maternal
mitochondria that would then theoretically be “incompatible” with
half of their nuclear DNA. Human outbreeding has introduced extensive
mitochondrial and nuclear genomemixingwithout obvious adverse ef-
fects to offspring. Admittedly, potential effects may for the moment re-
main hidden, and there is therefore a need for further understanding of
mitonuclear mismatch. However, mitochondrial transfer currentlyappears to be a mere extension of the natural genome mixing that is
common amongst humans today.
4. Clinical applications of mitochondrial transfer
4.1. Prevention of mtDNA disease
Mitochondrial transfer techniques have the potential to provide pa-
tientswith novel reproductive options for the prevention ofmtDNAdis-
ease. To date, women who are at risk of transmitting mtDNA disease to
their children have to turn to donor oocytes or pre-implantation genetic
diagnosis (PGD). However, both options have their limitations. The use
of donor oocytes results in the intendingmother being genetically unre-
lated to her child. PGD on the other hand is relatively unsuccessful in de-
tecting mtDNA mutations, especially in women who carry a high
mutational load in their oocytes and lowmutational load in cells outside
the ovaries. Typically, PGD work up is conducted using maternal lym-
phocytes to detect the mutation and optimise the PGD test. In addition,
PGD does not offer any therapeutic or preventative solutions if all the
embryos obtained are affected (and therefore untransferrable). Conse-
quently, it is important rather to focus on eliminating mutant mtDNA
completely from the embryo, possibly through mitochondrial transfer.
4.2. Aging oocytes
Mitochondria are the primary source of intracellular production of
reactive oxygen species (ROS). The association of ROS, aging and meta-
bolic decline is a theory that was established 60 years ago (Harman,
1956). Increased ROS levels lead to decreased metabolic function and
energy production, stemming from mutated mitochondrial respiratory
chain proteins which cause partial uncoupling of the respiratory chain.
Continuous accumulation of mutations arising from age-related ROS
also affects the potential of the mtDNA genome to replicate. Therefore,
aging begins at the molecular level and then progresses to cell, tissue
and ﬁnally organ dysfunction (Kirkwood, 2005, 2008). The mutation
rate of mtDNA is approximately 15 times that of the nuclear genome.
The mitochondrial genome replicates much more often and indepen-
dently from the nucleus. Furthermore, in comparison to the nuclear ge-
nome, mtDNA lacks protective histones and the DNA repair
mechanisms are deﬁcient (Richter, 1995; Mecocci et al., 1999).
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their 30s is becoming increasingly common. Female reproductive phys-
iology has not kept upwith relatively recent social and cultural tenden-
cies resulting in age-related infertility, aneuploidy and fetal defects in
women of advanced maternal age (Hook, 1981; Huang et al., 2008;
Allen et al., 2009; Bentov et al., 2011). Key causative factors are mito-
chondrial dysfunction from accumulation of mtDNA mutations and ac-
cumulation of oxygen radicals (Reynier et al., 2001; Bartmann et al.,
2004; Bentov et al., 2011). Aneuploidy can be explained by the fact
that resumption of meiosis during oocyte maturation requires a signiﬁ-
cant amount of energy, sourced from mitochondrial oxidative phos-
phorylation. Furthermore, fertilisation potential of oocytes and
developmental potential of embryos are heavily dependent on adeno-
sine 5-triphosphate (ATP), mtDNA content and mtDNA copy number
(Reynier et al., 2001; Van Blerkom, 2011). Infertility can also be
accounted for by poor implantation rates, another energy-demanding
process (Bartmann et al., 2004). Moreover, mitochondrial copy number
in oocytes of patients where the cause of fertilisation failure was un-
known was decreased when compared to oocytes from patients who
experienced IVF failure stemming from severe sperm defects. This
group predicted that a low mtDNA copy number results from faulty
ooplasm maturation.
Through mitochondrial transfer, all of these infertility issues could
potentially be overcome via introduction of large amounts of healthy
mitochondria, which will be able to supply the necessary amount of
ATP required for fertilisation and normal embryo development. Novel
techniques such as ST will offer women, who have experienced repeat-
ed IVF failure unrelated to severe sperm defects, have unexplained fer-
tility or are of advancedmaternal age, an increased chance of conceiving
a healthy child.
4.3. Diabetic mothers-to-be
Some studies have revealed that women suffering from diabetes
mimic older mothers-to-be in their poor reproductive outcomes,
experiencing increased rates of aneuploidies, miscarriages and birth de-
fects. These factors have been attributed to mitochondrial dysfunction
(Bentov and Casper, 2013). In a diabetic patient this is believed to be re-
lated to high oxidative stress (Maritim et al., 2003),which leads to alter-
ations in mitochondrial ultrastructure, increased mtDNA copy number
and reduced levels of ATP and tricarboxylic acid (TCA) cyclemetabolites
(Calabrese et al., 2005). The increase in mtDNA copy number is surpris-
ing and suggests thatmaternal diabetes either stimulatesmitochondrial
biogenesis or inhibits degradation in oocytes (Wang et al., 2009). Stud-
ies in mice have conﬁrmed that ovulated oocytes in diabetic mice pres-
ent with an elevated frequency of aneuploidies, caused by spindle
defects and chromosome misalignment during meiosis (Wang et al.,
2009). These researchers also concluded that oocytes develop abnor-
mally due to the toxic diabetic environment, which triggers mitochon-
drial damage. This correlation between mitochondrial dysfunction and
insulin resistance has led to the belief that offspring developing from
oocytes containing defective mitochondria may be predisposed to obe-
sity and insulin resistance. Abnormal mitochondrial metabolismmay in
thisway be responsible for inter-generational transmission ofmetabolic
disease (Turner and Robker, 2015). By introducing the nuclear genome
of affected mothers into healthy oocytes that possess undamagedmito-
chondria, diabetic women would hypothetically have an improved
chance of falling pregnant with a healthy fetus.
5. Conluding remarks and prospectives
On the basis of a detailed technical and ethical feasibility assessment,
only pronuclear and spindle transfer has been considered for human
clinical trials. They are the techniques that have been mentioned both
in an ethical review of mtDNA disease prevention by the Nufﬁeld
Council on Bioethics (2012), as well as in the Human Fertilisation andEmbryology Authority (HFEA) public debates and review reports
(summarised in an updated 2014 HFEA review, which can be accessed
at:
http://www.hfea.gov.uk/docs/Third_Mitochondrial_replacement_
scientiﬁc_review.pdf).
In February 2015, the UK Parliament voted in favour of amendment
to the Human Fertilisation and Embryology Act 2008 to legalise human
mitochondrial replacement and commence human clinical application.
The Human Fertilisation and Embryology (Mitochondrial Donation)
Regulations 2015 came into force on 29th October 2015 and can be
accessed at:
http://www.legislation.gov.uk/uksi/2015/572/pdfs/uksi_20150572_
en.pdf
However, only one case of human pronuclear transfer has been re-
ported, and it was performed in abnormally fertilised zygotes (Craven
et al., 2010). Spindle transfer has been explored more extensively,
with studies performed in rhesus macaques, resulting in the birth of
healthy offspring which presented with normal growth curves into
adulthood and extremely low levels of mtDNA carryover. The macaque
studies were conducted for three years after birth and no further follow
up has been reported.Human spindle transfer has yielded blastocyst de-
velopment and ESC isolation with the passaging of karyotypically nor-
mal differentiated cell lines (Tachibana et al., 2009, 2013). Potential
concerns with pronuclear and spindle transfer include the impact
these procedures might have on the risk of mtDNA carryover during
karyoplast transfer, embryogenesis, epigenetics and genome integrity
(Craven et al., 2011). These issues need to be carefully assessed through
more in-depth research.
Although spindle transfer has resulted in the birth of healthy pri-
mate offspring, unforeseen difﬁculties arosewhen the same group of re-
searchers applied the technique to mature human oocytes (Tachibana
et al., 2009, 2013). Further investigation is needed to establish long-
term safety and efﬁcacy of human pronuclear and spindle transfer for
clinical applications. Rhesus macaque studies have provided promising
results with the absence of any abnormalities into adulthood
(Tachibana et al., 2013). Future clinical trials should focus on optimisa-
tion of the techniques to reduce mutated mtDNA carryover to less than
the current 1% and tominimise the rate of abnormal fertilisation (Amato
et al., 2014). Moreover, the possible effects of exposing chromosomes
and spindles to polarised light birefringence need to be examined. An-
euploidy also needs to be reduced, as abberant segregation of chromo-
somes during maturation (metaphase II) is more frequent in aged
oocytes (Battaglia et al., 1996). Other difﬁculties include achieving
synchronised ovarian stimulation of the donor and recipient women
as oocyte aspirationwill need to take place on the same day. Clinical ap-
plication of STwill most likely need to utilise cryopreserved oocytes due
to these logistical hurdles, for which the techniques will need to be
optimised. Cryopreservation of the spindle donor oocyte (affected)
rather than the mitochondrial donor oocyte is advised, as primate stud-
ies have demonstrated that cytoplasts are more susceptible to damage
post vitriﬁcation than are spindles (Tachibana et al., 2013).
Understandably, any novel clinical treatment requires constructive
criticism and an evaluation of associated risks. Mitochondrial transfer
will surely progress to human clinical trials for the prevention of
mtDNA disease in the relatively near future and spread beyond the bor-
ders of the UK. This conclusion is based on the success that has been
achieved in animal models, human preimplantation embryos and the
lack of mitonuclear incompatibility in mixed race humans. In addition,
donor mtDNA may be matched to the affected mother's haplotype to
further eliminate concern of mitonuclear incompatibility (Burgstaller
et al., 2015).
One alternative to using mtDNA transfer for germ line therapies is
the use of therapeutic cloning (a technically similar micromanipulation
technique) for the generation of personalised stem cells. Although eth-
ically challenging, this method could offer patients already suffering
from mtDNA disease a novel treatment option. Since induced
46 A.S. Reznichenko et al. / Applied & Translational Genomics 11 (2016) 40–47pluripotent stem cells (iPSCs) from these patients would still contain
mutatedmtDNA, stem cells could be harvested from embryos produced
through somatic cell nuclear transfer to donor oocytes, which carry
healthymitochondria (Greggains et al., 2014). Using adult skin and am-
nion ﬁbroblasts, a recent report has demonstrated that human nuclear
transfer (NT) embryos contain very low levels of somatic cell mtDNA,
with heteroplasmy levels below those found in MII spindle transfer
human embryos (Greggains et al., 2014). This minimal level of mtDNA
carryover highlights the suitability of SCNT for therapeutic use in
mtDNA disease patients. However, this type of therapy would only
treat the affected person and not offer prevention of transmission of
mutated mtDNA to consecutive generations.
Another emerging technique that has been applied in a murine
model is the use ofmitochondria-targeted nucleases that can selectively
eliminate mutated germ line mtDNA. Similarly to therapeutic cloning,
this approach avoids the need for mtDNA transfer as it induces a shift
in the mtDNA heteroplasmy thereby preventing transmission of the
mutant haplotypes to offspring (Reddy et al., 2015).
Mitochondrial transfer, though yet to be perfected, will prospective-
ly offer affectedmothers-to-be the opportunity to conceive a genetically
related healthy child that only carries donor mtDNA. These techniques
introduce promising reproductive options to patients who at the mo-
ment have to rely on the use of donor oocytes or unreliable and relative-
ly unsuccessful PGD. Mitochondrial transfer can also be of clinical
beneﬁt to mothers-to-be suffering from diabetes, women of advanced
maternal age, or patients that have suffered IVF failure that is not attrib-
utable to a male factor. The novel methods discussed in this paper also
have the potential to expand research avenues in personalised stem
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